APA

Assadi M., Rezaei S., Jafari E., Rekabpour S. J., Ravanbod M. R., Zohrabi F., Amini A., Keshmiri S., Dadgar H. & Ahmadzadehfar H.Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years. : World journal of nuclear medicine.

Chicago

Assadi Majid, Rezaei Samira, Jafari Esmail, Rekabpour Seyed Javad, Ravanbod Mohammad Reza, Zohrabi Farshad, Amini AbdulLatif, Keshmiri Saeid, Dadgar Habibollah and Ahmadzadehfar Hojjat.Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years. : World journal of nuclear medicine.

Harvard

Assadi M., Rezaei S., Jafari E., Rekabpour S. J., Ravanbod M. R., Zohrabi F., Amini A., Keshmiri S., Dadgar H. and Ahmadzadehfar H.Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years. : World journal of nuclear medicine.

MLA

Assadi Majid, Rezaei Samira, Jafari Esmail, Rekabpour Seyed Javad, Ravanbod Mohammad Reza, Zohrabi Farshad, Amini AbdulLatif, Keshmiri Saeid, Dadgar Habibollah and Ahmadzadehfar Hojjat.: World journal of nuclear medicine. .